Navigation Links
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Date:3/13/2008

al neuropathy.

About Multiple Myeloma

Multiple myeloma is the second most common hematological malignancy and although the disease is predominantly a cancer of the elderly (the median age of onset is 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 55,000 individuals have multiple myeloma and approximately 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co- promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 85,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis synd
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products
2. New Legal Momentum Publication Exposes How Abstinence-Only Programs Harm Women and Girls
3. Fourth Annual James E. Marshall OCD Foundation Beyond Beauty Dinner to Honor E. Scott Beattie, Chairman and CEO, Elizabeth Arden, Inc. and Charles H. Townsend, President and CEO, Conde Nast Publications
4. Bojan M. Kuure Recognized by Strathmores Whos Who Worldwide Publication
5. Nature publication on pain research
6. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
7. Fry Construction Is Featured in Key Industry Publication
8. GSA confers 2007 Richard Kalish Innovative Publication Award to USCs Mather
9. Telemedicine publication expands coverage
10. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
11. Johnson & Johnson Tops Annual Pharmaceutical Company Rankings in a New Report From Industry-Leading Publication Scrip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... 28, 2015 Coffee could not only perk ... you from gum disease, researchers have found. , They found ... , Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, ... at Boston Univ. Henry M. Goldman School of Dental Medicine ... 2014 issue of the Journal of Periodontology. , “This is ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of its ... and coolest applications on the market for iOS, Android, ... technology expert, conducted the app review and shared with ... with knights, nature, and peasants. , The first ... Eurogamer. The popularity of these games grew over the ...
(Date:3/28/2015)... With more than 4,500 scientists, clinicians and ... and musculoskeletal diseases gathered here for the World ... time in the 17-year history of the field’s ... is an emerging non-pharmaceutical protocol for enhancing bone ... Wolff’s law, osteogenic loading at multiples of body ...
(Date:3/28/2015)... California-based leading wig brand UniWigs has prepared a mysterious ... the Easter Holidays from today until April 6th. There ... Day. , As the winter fades and spring approaches, ... with religious origins to countries in Europe and the ... best wig provider, UniWigs, would like to offer a ...
(Date:3/28/2015)... 2015 India Network visitor health ... available to all visitors who purchase the plan before ... are encouraged to purchase the insurance program as soon ... proper coverage for pre-existing medical conditions. Parents and grandparents ... medical conditions with serious consequences to their health. Many ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3
... Nov. 4 Online community member Emimi shares the ... that the support of an online community and talking to others ... related challenges. When she finally did become pregnant, she wanted to ... so by logging on to the My Community section of ...
... ST. PAUL, Minn., Nov. 4 The H1N1 strain may ... school nurses in Minnesota who are celebrating 100 years of ... Friday, November 6th will honor the ten decades of valuable ... and communities. , Never ones to miss an ...
... Nov. 4 The United States and the Commonwealth ... suit in the Western District of Virginia against the ... and Keystone Education and Youth Services LLC, the Justice ... Marion Youth Center, a residential facility in Marion, Va., ...
... patients on the heart-lung machine improved survival, study found ... for people who had coronary bypass surgery "off-pump," meaning ... than for those undergoing the conventional procedure, a major ... in 10 patients getting the off-pump procedure had died, ...
... WAYNE, Pa., Nov. 4 Qualsec (OTC Bulletin Board: QLSZ; ... Dr Robi Ludwig, Psy.D., a nationally known psychotherapist and award ... Dr Ludwig will make appearances, on behalf of VitaminSpice, on ... News Talk Shows and satellite radio stations. , Dr ...
... KNDL ), a leading, global full-service clinical research organization, today ... diluted share for the third quarter of 2009, primarily the ... with net income of $9.4 million or $0.62 per diluted ... forma basis, excluding the additional non-cash interest and restructuring charge, ...
Cached Medicine News:Health News:Regence's Social Media Web Site Gets a Facelift 2Health News:The Minnesota Nurses Association: School Nurses in Minnesota Celebrate 100 Years of Addressing Health Needs of School Children 2Health News:United States Intervenes in False Claims Act Suit Against Virginia Medicaid Providers 2Health News:Poorer Outcomes After 'Off-Pump' Bypass Surgery 2Health News:Poorer Outcomes After 'Off-Pump' Bypass Surgery 3Health News:Nationally Known Psychotherapist Dr. Robi Ludwig Joins Qualsec's Wholly-Owned Subsidiary VitaminSpice 2Health News:Kendle Announces Third Quarter 2009 Results 2Health News:Kendle Announces Third Quarter 2009 Results 3Health News:Kendle Announces Third Quarter 2009 Results 4Health News:Kendle Announces Third Quarter 2009 Results 5Health News:Kendle Announces Third Quarter 2009 Results 6Health News:Kendle Announces Third Quarter 2009 Results 7Health News:Kendle Announces Third Quarter 2009 Results 8Health News:Kendle Announces Third Quarter 2009 Results 9Health News:Kendle Announces Third Quarter 2009 Results 10
(Date:3/27/2015)... Quebec , March 27, 2015  Valeant Pharmaceuticals ... today the closing of its previously announced registered offering ... (the "Offering"). Pursuant to the Offering, the ... $199.00 per share, for aggregate gross proceeds of approximately ... with the U.S. Securities and Exchange Commission a final ...
(Date:3/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... announced that they have entered into an ... proprietary sd-rxRNA® technology for use in developing ... the potential to result in novel, more ... could be a significant step toward personalized ...
(Date:3/27/2015)... , March 27, 2015  WebMD Health ... source of health information, today announced an ... National Action Plan for Combating Antibiotic-Resistant ... emphasized the urgency and importance of addressing ... and global health.    The WebMD ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... Calif., Aug. 12 Founder of the Dermatology Institute, Peter Rullan, ... Perfect™ treatments to his patients with the purchase of the ... excited to add this new service for our patients," Dr. Rullan ... wanted to find a system that not only met my patients, ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: www.pdl.com . ... logo are considered trademarks of PDL BioPharma, Inc. ... release contains forward-looking statements. Each of these forward-looking statements ... from those, express or implied, in these forward-looking statements. ...
Cached Medicine Technology:Chula Vista's Dr. Peter Rullan Adds Alma Lasers' Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients 2PDL BioPharma Receives Letter from Genentech Relating to European Patents 2
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: